Presentation is loading. Please wait.

Presentation is loading. Please wait.

Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants  Ugo Pastorino, MD, Roberto Boffi, MD, Alfonso Marchianò, MD,

Published byWinifred Palmer Modified over 6 years ago

Similar presentations

Presentation on theme: "Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants  Ugo Pastorino, MD, Roberto Boffi, MD, Alfonso Marchianò, MD,"— Presentation transcript:

1 Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants 
Ugo Pastorino, MD, Roberto Boffi, MD, Alfonso Marchianò, MD, Stefano Sestini, MD, Elena Munarini, PhD, Giuseppina Calareso, MD, Mattia Boeri, PhD, Giuseppe Pelosi, MD, Gabriella Sozzi, PhD, Mario Silva, MD, Nicola Sverzellati, MD, Carlotta Galeone, PhD, Carlo La Vecchia, MD, Arianna Ghirardi, PhD, Giovanni Corrao, PhD  Journal of Thoracic Oncology  Volume 11, Issue 5, Pages (May 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Flow diagram of inclusion criteria in the current study from previous pilot and Multicentric Italian Lung Detection (MILD) trials. Thirty subjects from the pilot study were randomized in the MILD trial after 5 years of screening. LDCT, low-dose computed tomography. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Kaplan-Meier overall mortality experienced by current and former smokers. Patients who still smoked and those who had stopped smoking during the last screening visit were regarded as current and former smokers, respectively. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Effect of smoking cessation on overall mortality. Hazard ratios (Cox model) and corresponding 95% confidence intervals estimating the effect of smoking cessation on mortality. Estimates are adjusted for covariates measured at baseline (sex, age, predicted forced expiratory volume in the first second of expiration, and average number of pack-years) and during follow-up (lung cancer detection and smoking status). HR, hazard ratio; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants  Ugo Pastorino, MD, Roberto Boffi, MD, Alfonso Marchianò, MD,"

Similar presentations

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Long-Term Surveillance of Ground-Glass Nodules: Evidence from the MILD Trial  Silva Mario, MD, Sverzellati Nicola, MD, PhD, Manna Carmelinda, MD, Negrini.

Long-Term Surveillance of Ground-Glass Nodules: Evidence from the MILD Trial  Silva Mario, MD, Sverzellati Nicola, MD, PhD, Manna Carmelinda, MD, Negrini.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Screening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer  Mario Silva, MD, Carlotta Galeone, PhD, Nicola Sverzellati,

Screening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer  Mario Silva, MD, Carlotta Galeone, PhD, Nicola Sverzellati,
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer  Martin Reck, MD, PhD, Normand Blais,

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer  Martin Reck, MD, PhD, Normand Blais,
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

Similar presentations

Ads by Google